EGFR and non-small cell lung carcinoma: It was found that treatment of EGFR and VEGFR expressing NSCLC (NCI-H441 and SK-MES-1) with Dp (5–60 μM, 3 h) leads to downregulation of EGF- and VEGF-provoked and constitutive EGFR and VEGFR expressions, respectively.